We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




类风湿性关节炎检测预测患者对药物的反应

By LabMedica International staff writers
Posted on 15 Feb 2016
Print article
图片:Vectra DA疾病活动度检测工具检测和评定12种与类风湿性关节炎(RA)相关的血清蛋白(照片由Crescendo Bioscience)。
图片:Vectra DA疾病活动度检测工具检测和评定12种与类风湿性关节炎(RA)相关的血清蛋白(照片由Crescendo Bioscience)。
一种检测类风湿性关节炎严重程度的诊断工具有助于指导患者选择生物性或非生物性药物,通过预测其对不同治疗药物和治疗策略的反应实现这一选择。
这种检测类风湿性关节炎疾病活动度的多种生物标记物血液检测工具将与类风湿性关节炎活动度相关的12种血清蛋白质的浓度合并为一个客观评分,评分在1-100分范围内,帮助医生做出信息含量更大的治疗决策。
Helsingborg Hospital(Sweden)的科研人员近期开展了一项研究,评价是否能将Vectra DA评分用于预测157名类风湿性关节炎患者的最佳二线治疗方案,这些患者对免疫抑制剂甲氨蝶呤(MTX)反应不完全。结果显示,对于MTX反应不完全的早期RA患者,Vectra DA检测能预测二线治疗药物三联疗法相对于抗TNF的相对疗效。Vectra DA评分大于44分时,指示疾病具有高度活动度。
Vectra DA由Crescendo Bioscience(South San Francisco,CA,SA)生产。另外两项研究显示,Vectra DA能指导医生终止治疗。其中一项研究发现,Vectra DA评分高和单一生物标志物检测结果为阳性的患者治疗后复发率为76%,相比之下Vectra DA评分低的患者治疗后复发率为32%。第三项研究发现,Vectra DA评分高与患者逐渐撤销治疗后疾病的复发相关。Vectra DA有助于辨别临床症状改善、但潜在的高疾病活动性水平的患者,这类患者容易复发或突发疾病。
Crescendo的首席医疗官,Elena Hitraya医学博士说明:“免疫抑制剂甲氨喋啶是类风湿性关节炎的一线治疗药物,但是,这种药物并非对所有患者都有效。鉴于此,医生需要为患者选择治疗方案。可以选择的治疗方案包括增加一种合成的生物药物,或增加一种生物药物,最常用的是抗肿瘤坏死因子(TNF)。”本研究在2015年11月7-11日,在旧金山(CA,USA)召开的美国风湿病学会/美国风湿病卫生专业人员协会(ACR/ARHP)会议上公布。

Related Links:
Helsingborg Hospital 
Crescendo Bioscience 


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.